What Every Woman Should Know About Her Brain, Hormones & Mental Health

Summary

The episode explores how hormonal changes can affect women’s mood, attention, pain, and sense of self, while emphasizing that research and treatment options remain limited. The guest, a neuroscientist focused on brain stimulation and women’s mental health, argues that women’s experiences should guide research—and that care should offer individualized options rather than assume one treatment works for everyone.

Women’s brain health is under-researched

• The host opens by stating that fewer than 0.5% of brain-imaging studies focus on conditions affecting women.
• The guest describes how research funding and academic priorities have often made women’s health difficult to study. She says women’s cycles may add complexity to research, but that complexity has sometimes been treated as a reason not to investigate.
• She also highlights gaps between research and access: a treatment can be studied or developed without being affordable, reimbursed, or available to the people who need it.
• In her view, industry-funded studies can help fill gaps, but companies should be transparent. She describes her company’s approach as funding independent academics to conduct and analyze studies.

Brain stimulation and depression

The guest explains that the brain communicates through both chemical signaling and electrical activity. Many psychiatric medications act on chemical systems, while brain stimulation aims to influence electrical activity and communication between brain networks.

She describes two approaches:

• Transcranial magnetic stimulation (TMS): A treatment used for depression that aims to affect brain networks involved in mood and emotion regulation.
• Transcranial direct current stimulation (tDCS): A form of low-level stimulation that, according to the guest, can be used at home.

She says her interest in women’s mental health grew while studying depression and hearing women connect the onset of mood symptoms with events such as postpartum changes, perimenopause, or recurring premenstrual symptoms.

PMDD: severe symptoms, not simply “bad PMS”

• Premenstrual dysphoric disorder (PMDD) is described as a severe condition involving symptoms such as low mood, anxiety, irritability, and impulsivity in the days or weeks before a period.
• The guest says it affects at least 1 in 20 women and is likely underdiagnosed. The episode also cites a figure that 70% of women with PMDD experience suicidal ideation, underscoring that it should not be treated as merely a bad mood.
• PMDD can feel like a dramatic change in personality or perspective. The guest says symptoms may make relationship or work problems feel existential, even when the immediate trigger seems minor.
• The guest recommends taking suicidal thoughts or severe symptoms seriously and seeking appropriate clinical support.

Proposed explanation for PMDD

The guest stresses that PMDD is not generally explained by unusually high or low hormone levels. She says many people with PMDD have hormone levels within typical ranges, so a hormone test alone cannot confirm or rule out the condition.

Her proposed explanation is that some people’s brains respond differently to normal hormonal changes:

• Progesterone rises during the luteal phase of the menstrual cycle.
• Progesterone is converted into allopregnanolone, which interacts with GABA receptors, involved in calming activity in the brain.
• In PMDD, this interaction may have a paradoxical effect, contributing to anxiety or other symptoms rather than calm.
• The guest discusses possible genetic differences in GABA receptors, but presents this as an emerging explanation, not a settled account.

She also describes research suggesting that brain activity in the luteal phase can resemble patterns seen in major depression. These explanations are presented as developing research, not as definitive diagnostic tests.

PMDD, ADHD, and mood changes across the cycle

The guest describes a possible overlap between PMDD and ADHD:

• ADHD involves challenges with attention, reward processing, and shifting between brain networks involved in focused attention and mind-wandering.
• The prefrontal cortex is discussed as important to both attention regulation and emotional regulation, which may help explain why ADHD and PMDD can co-occur.
• Some women report that ADHD symptoms worsen or stimulant medication feels less effective in the luteal phase. The guest suggests that dose changes may be worth discussing with a psychiatrist, rather than making changes independently.
• The idea that the brain may “remember” or reconnect with a previous luteal-phase pattern is presented as an early hypothesis.

PMDD can also be confused with bipolar disorder because both may involve periods that feel very different from one another. The speakers say that tracking whether symptoms reliably follow the menstrual cycle can help clarify the pattern, while noting that conditions can co-occur and professional assessment may be needed.

Treatment options and the episode’s “buy or bye-bye” discussion

The speakers repeatedly emphasize that responses vary and that treatment often involves trial and error.

• Contraception and antidepressants: The guest identifies these as commonly used or approved PMDD treatments. Contraception may reduce hormonal fluctuations; antidepressants may help with low mood and related symptoms. They may be used continuously or, in some cases, only during the luteal phase. The guest says the choice and schedule should be tailored with clinical support, and that symptoms can return after stopping.
• Progesterone: The guest cautions that some people with PMDD may be sensitive to progesterone, so adding it can worsen symptoms. She does not rule out hormonal treatments generally, but rejects the idea that one formulation is a universal fix.
• TENS for period pain: The guest is broadly supportive. She says a TENS device may help block pain signals and can be more useful alongside other measures, such as heat and pain relief, than as a sole strategy for intense pain.
• Lion’s mane: The guest says evidence is limited and advises caution about supplement quality and possible medication interactions. She warns against claims that it will fix PMDD.
• Creatine: She supports it mainly for muscle-related benefits, while describing claims about cognitive benefits as still emerging.
• Chasteberry: The guest says evidence for mood symptoms is not strong. The host reports an individual benefit for breast tenderness, which they distinguish from evidence that it treats PMDD mood symptoms.
• Saffron: The guest describes it as a possible add-on, citing a proposed interaction with GABA-related pathways, but says it should not replace medical care for severe PMDD.
• Antihistamines: The guest acknowledges reports of rapid symptom relief but advises caution about using them long-term without clinical guidance. She raises possible side-effect and nutrient-absorption concerns; these are her cautions in the discussion, not a treatment recommendation for viewers.

Tracking symptoms and managing the impact

The speakers recommend learning an individual pattern rather than relying on generic cycle advice:

• Track symptoms across at least two cycles when seeking a PMDD assessment, as the guest describes this as part of retrospective diagnosis.
• Record the symptoms that actually matter to the individual—such as tearfulness, irritability, impulsivity, or medication changes—not just the limited options offered by an app.
• Use tracking to create perspective: when a difficult phase is predictable, it may help to postpone major decisions and revisit them when symptoms have eased.
• The guest cautions against apps that give blanket advice about exercise or productivity based only on cycle phase. Cycles and symptoms differ, and tracking should support listening to one’s own body rather than replace it.
• The speakers also stress checking how apps handle personal data.

The host shares that sleep, nutrition, stress reduction, limiting alcohol, and communicating with her partner have helped her manage symptoms. Both speakers emphasize that practical strategies may help, but should not be treated as a substitute for care when symptoms are severe.

Relationships, support, and stigma

The host describes how explaining PMDD to her partner changed his response to her symptoms. The guest says supportive partners, friends, or family can make it easier to manage PMDD and seek care. They discuss couples therapy as a potentially useful option, while recognizing that it will not suit every relationship.

They also argue that symptoms are often minimized or mistaken for personality flaws. The guest says community discussion and women sharing experiences can help people recognize patterns and generate research questions, even though personal accounts are not the same as controlled trials.

The guest’s wearable device

The guest describes a wearable headband developed by her company that uses tDCS to stimulate the prefrontal cortex. She says it is intended to support mood and pain symptoms associated with periods, and that users apply it for about 20 minutes a day. She presents it as a drug- and hormone-free option that may be used alongside other treatments.

She says the company has completed PMDD clinical trials and submitted them to regulators, and is also studying the device for endometriosis-related pelvic pain. These are the guest’s descriptions of the product and its research status; the episode does not independently evaluate those claims.

Central lesson

The guest’s closing message is that women are experts on their own experiences. Research and clinical care should take those experiences seriously, ask better questions, and provide more personalized options.

Speakers and sources mentioned

Speakers

• Dr. Faye Bate — Host.
• Dr. Emilė Radytė — Neuroscientist and guest, identified in the video metadata as the founder of Samphire Neuroscience. The auto-generated subtitles render her name inconsistently, including “Emily Rutledge” and “Dr. Amy.”

Other sources or organizations mentioned

• Samphire Neuroscience — The guest’s company, discussed in connection with its wearable brain-stimulation device and research.
• Harvard and Oxford — The guest’s educational and research background.
• NHS — Mentioned in relation to clinical guidance, reimbursement, and a research collaboration.
• FDA, ICD-11, and DSM-5 — Mentioned in discussion of treatment approval and recognition of PMDD.
• Natural Cycles — Named as an example of a cycle-tracking service.
• Unspecified research — The speakers refer to brain-imaging findings, a meta-analysis of period-tracking-app claims, clinical trials, and emerging genetic and mouse-model studies. No full paper titles or authors are provided in the subtitles.